Aurobindo Pharma Limited has announced that its wholly-owned subsidiary Aurobindo Pharma Australia Pty Ltd has received its first approval from Therapeutic Goods Administration (TGA), Government of Australia for the registration of Auro-Lisinopril 5, Auro-Lisinopril 10 and Auro-Lisinopril 20 tablets containing Lisinopril (as dehydrate) 5mg, 10mg and 20mg.
The approval indications for these therapeutic products are for treatment of hypertension, congestive heart failure and acute myocardial infarction